- Gap review, remediation roadmap, and implementation support
- Policy package, evidence mapping, and submission prep
- Designed for primes and subs across non-tech and tech work
Antibacterial Nanoparticles Therapeutic (ANT) Study
Special Notice from DEFENSE HEALTH AGENCY (DHA) • DEPT OF DEFENSE. Place of performance: MD. Response deadline: Apr 28, 2026. Industry: NAICS 541713 • PSC AN13.
CMMC support options for this DoD solicitation
As DoD CMMC rollout expands, approximately 80%+ of DoD solicitations are expected to include cybersecurity/CMMC requirements, including many non-tech scopes.
- Structured checklist, AI guidance, and progress tracking
- Build evidence and controls with clearer next-step workflows
- Ideal for teams that want speed plus affordability
Market snapshot
Baseline awarded-market signal across all contracting (sample of 400 recent awards; refreshed periodically).
Related hubs & trends
Navigate the lattice: hubs for browsing, trends for pricing signals.
Applicable Wage Determinations
SAM WDOL references matched to this opportunity's location and scope language.
View more for this contract3 more WD matches and 78 more rate previews.↓
Point of Contact
Agency & Office
More in NAICS 541713
Description
The University of Notre Dame will conduct a study to test innovative antibacterial nanoparticles with phage-mimicking properties (PhANPs) against combat relevant multi-drug resistant (MDR) strains of Pseudomonas (P.) aeruginosa, bacterial pathogen to cause hard to treat and even deadly infections in service members after battlefield injuries. There is a need to bring novel therapeutics to the military health care to treat MDR P. aeruginosa. The collaborative partner of this study is the University of Notre Dame, the patent owner of a unique technology (phage-mimicking nanoparticles) that provides life-saving therapeutics for service members and civilians. This technology was awarded a patent in 2024 - US-12161725-B2. Government anticipates that the collaborative efforts will contribute to Food and Drug Administration (FDA) approval of this innovative therapy, leading to reduced morbidity and mortality rates, enhanced operational readiness, advanced combat medicine, and substantial contributions to broader biosecurity initiatives and civilian health improvements.
Files
Files size/type shown when available.
BidPulsar Analysis
A practical, capture-style breakdown of fit, requirements, risks, and next steps.
FAQ
How do I use the Market Snapshot?
It summarizes awarded-contract behavior for the opportunity’s NAICS and sector, including a recent pricing band (P10–P90), momentum, and composition. Use it as context, not a guarantee.
Is the data live?
The signal updates as new awarded notices enter the system. Always validate the official award and solicitation details on SAM.gov.
What do P10 and P90 mean?
P10 is the 10th percentile award size and P90 is the 90th percentile. Together they describe the typical spread of award values.